EDIFY™

MANA Therapeutics Announces Final Closing of Series A and Closing of Venture Debt Facility

Retrieved on: 
Tuesday, November 30, 2021
Health, Biotechnology, Patient, CEO, MANA, Â, Neoplasm, AML, Cancer, Antigen, Acute myeloid leukemia, Silicon Valley Bank, B cell, Science, Therapy, Pharmaceutical industry, Vaccine, EDIFY™, MANA Therapeutics, EDIFY™, MANA THERAPEUTICS

MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the final closing of its Series A financing, bringing the total raised to $42 million.

Key Points: 
  • MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the final closing of its Series A financing, bringing the total raised to $42 million.
  • In addition, MANA closed a $7.5 million venture debt facility with Silicon Valley Bank with an initial tranche of $5 million available immediately.
  • It will also permit building out our pipeline of MANA-512 candidates, which will apply new sets of antigens to the EDIFY platform.
  • MANA Therapeutics is harnessing the natural immune system to develop broadly accessible, ready-to-use cellular therapies to improve outcomes for cancer patients.

MANA Therapeutics Appoints Arthur Hurwitz as Chief Scientific Officer

Retrieved on: 
Monday, May 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Biology, Life sciences, Stem cells, Oncology, Biotechnology, Cell biology, Cell therapy, Agenus, Tumor antigen, EDIFY™, MANA Therapeutics, EDIFY™, MANA THERAPEUTICS

b'MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the appointment of Arthur (Andy) Hurwitz, Ph.D., to the newly created position of Chief Scientific Officer.

Key Points: 
  • b'MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the appointment of Arthur (Andy) Hurwitz, Ph.D., to the newly created position of Chief Scientific Officer.
  • Dr. Hurwitz previously served as Senior Vice President and Head of Research at MANA.
  • In addition, Michael Kuo MT (ASCP) has been appointed as Senior Vice President of Technical Operations.\nThis press release features multimedia.
  • Dr. Hurwitz was also Senior Director of TCR Biology at Agenus where he held responsibilities for both vaccine and cell therapy activities.

MANA Therapeutics Launches with $35 Million Series A Financing

Retrieved on: 
Friday, January 8, 2021
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Oncology, Tumor antigen, EDIFY™, MANA Therapeutics

MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced a $35 million Series A financing.

Key Points: 
  • MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced a $35 million Series A financing.
  • The financing was led by Cobro Ventures and Lightchain Capital, with participation from LifeSci Venture Partners and other undisclosed investors.
  • This Series A funding is enabling rapid progress with our programs, said Martin Silverstein, M.D., President and CEO of MANA Therapeutics.
  • MANA Therapeutics is harnessing the natural immune system to develop broadly accessible, ready-to-use cellular therapies to improve outcomes for cancer patients.